12 May 2025 [Press release]

Announcement of the Optimization of GenoQuest CA/GV qPCR Assay on the geneLEAD VIII

Following the announcement of the collaboration between DiagCor Life Science Ltd. (DiagCor) with Precision System Science Co., Ltd. (PSS), and successful optimization and implementation of the GenoQuest JAK2 qPCR Assay on the geneLEAD VIII, the All-in-One, fully automated Sample-to-Result system, we are pleased to add the GenoQuest CA/GV qPCR Assay to the list of optimized tests.

Candida albicans (CA) and Gardnerella vaginalis (GV) are the common causative agents of vaginitis, presenting in around 70% of cases. Clinically, both infections may be asymptomatic or develop symptoms which are similar to those of other types of vaginal infections. Nevertheless, the medication crucially depends on the type of infection. In addition, GV is the most common causative agent of bacterial vaginosis (BV), which is associated with increased risk for the acquisition of some STDs (e.g., HIV, N. gonorrhoeae, C. trachomatis, and HSV-2). Vaginal candidiasis may be diagnosed by examination under a microscope or fungal culture. However, the microbial culture and Cervical Pap test for GV diagnosis are not suggested because of their low sensitivity and specificity. The GenoQuest CA/GV qPCR Assay provides a simple, rapid and highly sensitive method to detect and differentiate CA and GV in less than 2 hours. Our new application note details an automated workflow for this assay on the geneLEAD VIII system, including its clinical performance.

If you would like to learn more about this platform, please contact our sales team at [email protected].

About DiagCor: Headquartered in Hong Kong with ISO 13485 accredited Quality Management System (QMS), DiagCor has been a pioneer in multiplex technologies via its global leader in Flow-through hybridization instruments and GenoFlow^TM assays, and is now growing an extensive portfolio of qPCR assays for in vitro diagnostics on open systems, covering the areas of infectious disease, oncology and human genetics.

About PSS: Headquartered in Chiba, Japan, PSS develops instruments for in vitro diagnostics. In addition to a proprietary, fully automated nucleic acid isolation system, the company offers multi-purpose magnetic bead-based open-platform instruments, including ready-to-use sample-to-results systems.